Sinusitis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

 Sinusitis is inflammation of the sinuses, which are air-filled cavities in the skull. Causes are a combination of environmental and host factors. Acute sinusitis is most commonly due to viruses and is usually self-limiting. Around 90% of individuals with common colds also experience viral sinusitis to some degree. Those with atopy commonly get sinusitis. It can be caused by allergens, fungi, viruses, irritants, and bacteria. Popular irritants are animal dander, polluted air, smoke, and dust. Sinusitis can be categorized into the following groups:

1.       Acute Rhinosinusitis: This condition is characterized by a sudden onset and typically lasts for less than 4 weeks, with symptoms resolving completely.

2.       Subacute Rhinosinusitis: Subacute rhinosinusitis represents a continuation of acute rhinosinusitis, but it persists for a duration of less than 12 weeks.

3.       Recurrent Acute Rhinosinusitis: This condition is defined by the occurrence of four or more episodes of acute rhinosinusitis, each lasting at least 7 days, within a single year.

4.       Chronic Rhinosinusitis: Chronic rhinosinusitis is diagnosed when signs and symptoms persist for 12 weeks or longer.

Most commonly, a viral upper respiratory infection causes rhinosinusitis secondary to edema and inflammation of the nasal lining and the production of thick mucus that obstructs the paranasal sinuses and allows a secondary bacterial overgrowth. There are frontal, maxillary, sphenoid, and ethmoid sinuses. Allergic rhinitis can lead to sinusitis also due to ostial obstruction. Ciliary immobility can lead to increased mucus viscosity, further blocking drainage. Bacteria are introduced into the sinuses by coughing and nose blowing. Bacterial sinusitis usually occurs after a viral upper respiratory infection and worsening symptoms after 5 days or persistent symptoms after 10 days. The most common malady mistaken for sinusitis is rhinitis or an upper respiratory infection. A maxillary toothache can also mimic the pain caused by maxillary sinusitis. Tension headaches, vascular headaches, foreign bodies, brain abscesses, epidural abscesses, meningitis, and subdural empyema can also be mistaken for sinusitis. Most cases of uncomplicated acute bacterial sinusitis (ABS) can be treated on an outpatient basis with a good prognosis. Frontal or sphenoid sinusitis with air-fluid levels may require hospitalization with intravenous (IV) antibiotics. Patients who are immunocompromised or are toxic appearing require admission. Fungal sinusitis is associated with high morbidity and mortality. The recommended initial treatment for uncomplicated acute sinusitis has traditionally been a two-week course of antibiotics, with amoxicillin being one of the preferred choices. The selected antibiotic should effectively target bacteria such as Streptococcus pneumoniae, Moraxella catarrhalis, and Haemophilus influenzae. This coverage is crucial because rare but intracranial severe and orbital complications of acute bacterial sinusitis are often associated with S. pneumoniae, particularly in individuals with compromised immune systems. Another suitable option for treating uncomplicated acute sinusitis is amoxicillin-clavulanate, which includes clavulanate, a beta-lactamase inhibitor that enhances coverage against H. influenzae and M. catarrhalis. Additional antibiotic choices for treating this condition include cephalosporins like cefpodoxime proxetil and cefuroxime. Patients with allergies to beta-lactam antibiotics can consider alternatives such as trimethoprim-sulfamethoxazole, clarithromycin, and azithromycin.

·       Sinusitis impacts approximately one in seven adults in the United States, which amounts to over 30 million individuals each year. This condition is more prevalent among adults compared to children.

Thelansis’s “Sinusitis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential SINUSITIS treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Sinusitis across the 8 MM market from the Centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Sinusitis Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Sinusitis – market outlook, epidemiology, competitive landscape, and market forecast report – 2022 to 2032